复发难治性多发性骨髓瘤的治疗进展  

Progress in the research and treatment of relapsed and refractory multiple myeloma

作　　者：朱晓峰[1] 汪安友[1] 蔡晓燕[1] 

机构地区：[1]安徽医科大学附属省立医院血液内科,合肥230001

出　　处：《临床医学》2014年第7期115-117,共3页Clinical Medicine

摘　　要：多发性骨髓瘤(MM)是一种以浆细胞恶性克隆增殖性疾病,目前仍为一种不可治愈的恶性血液系统疾病。几乎所有MM患者最终都将进入复发、难治阶段,对于复发、难治性MM的治疗仍是临床亟待解决的研究热点之一,随着造血干细胞移植技术的不断成熟以及近年来新型药物应用,如以免疫调节剂及蛋白酶体抑制剂等为基础的联合治疗,均明显改善了复发、难治性MM患者的临床预后,提高了缓解率和延长了生存期。本研究就近年来相关方面治疗研究进展做一综述。Multiple myeloma（ MM）is one of malignant plasma cells clone hyperplastic diseases. Almost all MM patients would be incurable,and eventually enter the stage of relapse and refractory. For patients with relapse,refractory MM,treatment is still one of the highlights for clinical research. With the development of stem cell transplantation and new drug applications, like immune modulators and the proteasome inhibitor based combination therapy,which significantly improved the response rate and prolong the survival in patients with relapse and refractory MM. This paper will summarize the treatment and research pro-gress of relapse and refractory MM in recent years.

关 键 词：多发性骨髓瘤 复发 难治 治疗进展 

分 类 号：R733.3[医药卫生—肿瘤]